Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, 3rd East Qingchun Road, Hangzhou, 310016, China.
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
BMC Health Serv Res. 2020 Mar 12;20(1):209. doi: 10.1186/s12913-020-5072-3.
The introduction of non-VKA oral anticoagulants (NOACs) has changed the landscape of preventing thromboembolism events in many countries. However, the prescription trends of oral anticoagulant (OAC) in China are still unclear, which were evaluated in this study through data extracted and summarized from 5 major cities as representatives.
This study was designed as a time-series study which was based on pharmacy prescription data. Analysis was performed on yearly aggregated visits and expenditure. The results were also stratified by indications and specialties.
A total of 189,006 prescriptions of 67 hospitals in 6 years were included in the study. The average growth rates of overall visit and expenditure of OAC were 15.8 and 57.5%, respectively. The share of warfarin decreased and NOACs had taken 92% of cost, covering 28% of patients in 2017. The more frequently used NOACs were rivaroxaban and dabigatran. The use of OAC was differed by indication and specialty.
The use of NOACs was found increasing rapidly in both visits and cost, sharing a majority of cost with a minority of patients. Attentions should be paid on the rational use of NOACs.
非维生素 K 拮抗剂口服抗凝剂（NOAC）的引入改变了许多国家预防血栓栓塞事件的格局。然而，中国口服抗凝剂（OAC）的处方趋势仍不清楚，本研究通过从 5 个主要城市提取和总结的数据进行了评估。
本研究设计为基于药房处方数据的时间序列研究。对每年汇总的就诊次数和支出进行了分析。结果还按适应证和科室进行了分层。
共纳入 6 年 67 家医院的 189006 份处方。OAC 的总就诊次数和支出的平均增长率分别为 15.8%和 57.5%。华法林的份额减少，NOAC 占成本的 92%，在 2017 年覆盖了 28%的患者。更常用的 NOAC 是利伐沙班和达比加群。OAC 的使用因适应证和科室而异。
NOAC 的使用在就诊次数和费用方面均呈快速增长趋势，占大多数费用的患者比例很小。应关注 NOAC 的合理使用。
